1. Skip to Menu
  2. Skip to Content
  3. Skip to Footer>

Act-T4 Cell™ kit

 

Clinical investigations into the presence and extent of antigen-specific T cell immunity are becoming more relevant at present. Therefore the necessity for antigen-specific functional CD4 T cell assays in routine diagnostic clinical laboratories is real.

Recently, a whole blood technique involving flow cytometry and detection CD25 and CD134 (OX40) expression on the surface of activated CD4+ T cells (OX40 assay) was demonstrated to be highly accurate. The results obtained were concordant with those obtained from more traditional methods of antigen-specific T cell detection. Several studies have validated the preclinical use of this method against virus (e.g., CMV, EBV, HCV, HIV) or bacteria (e.g., Mycobacterium tuberculosis), which can also be used to evaluate general immunocompentence against mitogens.


Act-T4 Cell™ kit is intended to be used after incubating whole blood during 44-48 hours in a culture medium with the antigens/mitogens of interest. The use of a positive control (mitogens such as phytohaemagluttinin or staphylococcal enteroantigen B) and a negative control (unstimulated whole blood) are highly recommended. The antibody combination proposed enables the selection of activated antigen-specific CD4+ T cells (CD3+CD4+CD134+CD25+ cells).

 

pdf

 Find more information in the Technical Notes document

 

Clinical investigations into the presence and extent of antigen-specific T cell immunity are becoming more relevant at present. Therefore the necessity for antigen-specific functional CD4 T cell assays in routine diagnostic clinical laboratories is real. Recently, a whole blood technique involving flow cytometry and detection CD25 and CD134 (OX40) expression on the surface of activated CD4+ T cells (OX40 assay) was demonstrated to be highly accurate. The results obtained were concordant with those obtained from more traditional methods of antigen-specific T cell detection. Several studies have validated the preclinical use of this method against virus (e.g., CMV, EBV, HCV, HIV) or bacteria (e.g., Mycobacterium tuberculosis), which can also be used to evaluate general immunocompentence against mitogens.

Act-T4 Cell™ kit is intended to be used after incubating whole blood during 44-48 hours in a culture medium with the antigens/mitogens of interest. The use of a positive control (mitogens such as phytohaemagluttinin or staphylococcal enteroantigen B) and a negative control (unstimulated whole blood) are highly recommended. The antibody combination proposed enables the selection of activated antigen-specific CD4+ T cells (CD3+CD4+CD134+CD25+ cells).

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our privacy policy.

I accept cookies from this site.

EU Cookie Directive Module Information